ストックスクリーナーアプリを入手
34.78
4.13%
1.36
前日終値:
$33.42
開ける：
$32.75
24時間の取引高:
7.79M
Relative Volume:
3.17
時価総額：
$3.96B
収益：
-
当期純損益:
$-284.08M
株価収益率:
-14.35
EPS:
-2.4234
ネットキャッシュフロー:
$-234.65M
1週間 パフォーマンス:
+141.33%
1か月 パフォーマンス:
+113.89%
6か月 パフォーマンス:
+578.36%
1年 パフォーマンス:
+235.26%
1日の値動き範囲:
$32.00
$35.15
1週間の範囲:
$13.93
$36.15
52週間の値動き範囲:
$3.72
$36.15
Cogent Biosciences Inc Stock (COGT) Company Profile
COGT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
34.80 | 4.62B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.24 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.79 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.97 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
898.37 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
374.85 | 36.43B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-16 | 開始されました | Stifel | Hold |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownWhat's Next? - MarketBeat
Cogent Biosciences Shares Slip After Announcing $500 Million Fundraising Plan - MSN
Cogent Biosciences stock falls after pricing $500 million offerings By Investing.com - Investing.com Australia
Cogent Biosciences stock falls after pricing $500 million offerings - Investing.com India
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $34.00 - MarketBeat
Cogent Biosciences (COGT) Boosts Stock Offering to $300 Million - GuruFocus
Cogent Biosciences Raises Nearly $500 Million For Growth - Finimize
Cogent Biosciences Prices $475 Million in Combined Equity, Convertible Notes Offerings - MarketScreener
Can Cogent Biosciences Inc. stock weather global recession2025 Key Lessons & Weekly Watchlist for Hot Stocks - newser.com
Cogent Biosciences (COGT) Upsizes Equity Offering to $475.3M - GuruFocus
Day 5 of Gains Streak for Cogent Biosciences Stock with 137% Return (vs. 328% YTD) [11/11/2025] - Trefis
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 - Investing News Network
Cogent Biosciences (NASDAQ: COGT) prices 9,677,420 shares at $31; plus convertible notes - Stock Titan
Cogent Biosciences Prices Public Offerings of Common Stock and Convertible Senior Notes Totaling Approximately $475 Million - Quiver Quantitative
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 - GlobeNewswire Inc.
Is Cogent Biosciences Inc. stock reversal real or fake2025 Market WrapUp & Free Technical Confirmation Trade Alerts - newser.com
Baird Maintains Cogent Biosciences (COGT) Neutral Recommendation - Nasdaq
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $50.00 at Leerink Partners - MarketBeat
Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial - Insider Monkey
Cogent Biosciences (NASDAQ:COGT) Upgraded by Wedbush to "Outperform" Rating - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Upgraded by Stifel Nicolaus to "Buy" Rating - MarketBeat
Comparing Cogent Biosciences Inc. in custom built stock radarsWeekly Profit Report & Growth Focused Entry Reports - newser.com
Cogent Biosciences: Soaring On Blowout GIST DataI Expect More Upside (NASDAQ:COGT) - Seeking Alpha
Cogent Biosciences slips as co eyes capital raise after stock surge - TradingView
Cogent Biosciences (NASDAQ:COGT) Hits New 1-Year High on Strong Earnings - MarketBeat
Baird Maintains Neutral Rating on COGT, Raises Price Target to $34 | COGT Stock News - GuruFocus
Wedbush Upgrades Cogent Biosciences to Outperform From Neutral, Raises Price Target to $38 From $13 - MarketScreener
Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation - Nasdaq
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - Investing News Network
Assessing Cogent Biosciences (COGT) Valuation After Strong Recent Share Price Surge - simplywall.st
Cogent Biosciences (COGT) Stock Soars with 135% Increase - GuruFocus
Cogent Biosciences stock hits 52-week high at 32.79 USD By Investing.com - Investing.com Australia
Cogent Biosciences’ Phase 3 PEAK Study Success Positions Company for Market Leadership and $1.1 Billion Peak Sales - TipRanks
How Cogent Biosciences Inc. stock benefits from tech adoptionSwing Trade & AI Based Buy/Sell Signal Reports - newser.com
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Cogent Biosciences (COGT) - The Globe and Mail
Cogent Biosciences price target raised to $45 from $30 at Jefferies - TipRanks
Cogent Biosciences (COGT): Assessing Valuation After a 119% One-Day Surge and 316% YTD Gain - Yahoo Finance
Biotech Mergers And Trial Successes Send Shares Higher - Finimize
Cogent Biosciences stock hits 52-week high at 32.79 USD - Investing.com India
Cogent Biosciences (COGT) Launches $400M Public Offerings - GuruFocus
Cogent Biosciences Launches Concurrent Public Offerings Worth $400 Million - MarketScreener
A second win for Cogent pushes the company toward two NDAs - BioWorld MedTech
Cogent Biosciences launches $400 mln equity, convertible deals after stock more than doubles - TradingView
Is Cogent Biosciences’ Bright Future Already Here? - timothysykes.com
COGT: Leerink Partners Raises Price Target to $50.00, Maintains Outperform Rating | COGT Stock News - GuruFocus
Cogent Biosciences announces proposed concurrent public offerings - MSN
Biotech Catapults 119% On A First-In-20-Years Development - Investor's Business Daily
Cogent Hits Mark In Phase III GIST Trial Of Bezuclastinib - Citeline News & Insights
Cogent Biosciences price target raised to $50 from $18 at Leerink - TipRanks
Cogent Biosciences: Promising Outlook with Breakthrough GIST Treatment and Strategic Growth Plans - TipRanks
Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy (COGT) - Seeking Alpha
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
Cogent Biosciences Inc (COGT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pinnow Cole | Chief Commercial Officer |
Jan 14 '25 |
Buy |
7.60 |
43,750 |
332,412 |
45,848 |
2.48%
0.82%
大文字化:
|
ボリューム (24 時間):